Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game

Benzinga

By Johnny Rice, Benzinga Erez Aminov, CEO & Chairman of the Board, and Dr. Itzchak Angel, Chief Scientific Advisor for MIRA Pharmaceuticals (NASDAQ: MIRA), were recently interviewed by Benzinga. MIRA is a pre-clinical biopharma focused on developing treatments for neurologic and neuropsychiatric disorders. It holds exclusive rights to Ketamir-2, an oral ketamine analog being studied for neuropathic pain, treatment-resistant depression, major depressive disorder with suicidal ideation and PTSD. The company’s other primary asset, MIRA-55, is a novel pharmaceutical marijuana analog that could provide enhanced therapeutic effects over THC. Watch the full interview here: Featured photo by Jeremy Bishop on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 03, 2024 08:25 AM Eastern Daylight Time

Video Image

Psilocybin's Potentially Revolutionary Ability To Treat Depression Hinges On FDA Approval – AJNA BioSciences Is Standardizing Raw Materials To Meet Guidelines

Benzinga

By Anthony Termini, Benzinga Results of research conducted at Emory University, the University of Wisconsin-Madison and UC Berkeley estimate that more than five million Americans suffering from depression could benefit from psilocybin-assisted therapy. This first-of-its-kind peer-reviewed study is scheduled to be published in the scientific journal Psychedelics on September 24, 2024. How Psilocybin Can Deliver Rapid And Sustained Antidepressant Effects This latest research report is not the first to look into the use of psilocybin to treat depression. There is a body of research showing that it can potentially deliver quick and continuous antidepressant effects. For example, results of randomized clinical trials have been published in the Journal of the American Medical Association and by the University of California San Francisco. In fact, psilocybin’s therapeutic properties had been researched as early as the 1950s by Swiss drugmaker Sandoz Group (OTC: SDZNY) as part of specific psychiatric studies. A Pioneering Drug Development Company Focused On Botanical Therapies All of this seems to support the work of AJNA BioSciences, based in Littleton, Colorado. The company could be strategically poised to lead and create value in this emerging category of pharmaceuticals. AJNA is currently developing a full-spectrum psilocybin “novel antidepressant.” AJNA believes that a standardized botanical medicine made from psilocybin will be in high demand. It reports that in 2020, doctors prescribed nearly $19 billion worth of drugs to treat depression. Researchers have estimated that the market for psychedelic drugs will grow annually by more than 12% through at least 2027. AJNA believes it can capture a high single-digit percentage of that market. What is significant about AJNA’s drug development work is that it is standardizing botanical materials to meet strict FDA guidelines. AJNA reports that it is the first biotech company working with botanicals under a DEA Schedule-1 license. AJNA is developing a daily-use anti-depression treatment through what it intends to be a fully characterized and FDA-approved formulation. AJNA has advanced the development of two prescription drug candidates: its CBD-based Autism Spectrum Disorder drug is anticipating a phase 2 trial in late 2024, and its psilocybin-based antidepressant drug has a phase 1 trial scheduled for early 2025. The company’s research team, led by scientists from Harvard, Johns Hopkins and New York University, is conducting clinical trials in the same manner as large drug manufacturers. However, AJNA is working to transform the pharmaceutical industry by pioneering a new regulatory pathway to produce drugs from plants. Why AJNA Is Focused On FDA Approvals Authors of the research to be published by Emory University, the University of Wisconsin-Madison and UC Berkeley say that their “projections are highly contingent on…precise FDA approval parameters.” In other words, how broadly or narrowly the FDA defines this new class of drugs. AJNA seems to have anticipated some of this. It reports that it has distinguished itself as one of the leaders in the evolving field of botanical drug development and has paid strict attention to how the FDA is defining the pathways for botanical drugs to get approved. Joel Stanley, AJNA’s CEO, says that FDA approval is a critical component of bringing new drugs to market. Federal law requires that a manufacturer show that the drugs they produce are safe and effective. Stanley also notes that without the FDA’s stamp of approval, a drug is unlikely to be considered for reimbursement by health insurance carriers. For botanical drugs to be an accepted component of a physician’s and patient’s routine treatment options, they must be approved by the FDA. AJNA is committed to producing natural botanical drugs that have undergone rigorous laboratory and clinical scrutiny to demonstrate that they deliver “nature, backed by science.” AJNA is currently raising capital in a crowdfunding round through Wefunder. Stanley says that “by investing in AJNA, you’re helping to change the healthcare paradigm to include optionality that none of us have ever had.” With less than a week before the current financing/investment opportunity closes, interested investors can find more information on the Wefunder website. Featured photo by Monika Schröder on Pixabay. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 02, 2024 08:25 AM Eastern Daylight Time

Image

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Velocity Global Named a Leader in NelsonHall’s Global Employer of Record (EOR) Evaluation for the Fourth Time in a Row

Velocity Global

Velocity Global, the world’s expert on work, announced today that it was positioned as a leader in the 2024 Vendor Evaluation & Assessment Tool (NEAT) for global EOR services by NelsonHall. The report recognizes Velocity Global for both its ability to deliver immediate customer benefits as well as its capabilities to meet future customer needs. This marks the fourth time in a row that Velocity Global has earned this distinction, solidifying its position as a trusted partner for companies expanding their global presence. "Deploying a global workforce is extremely complex, as companies need to navigate a maze of varying regulations, compliance needs, and talent expectations in different countries," said Jeanine Crane-Thompson, Principal Analyst at NelsonHall’s HR & Talent Transformation practice. "Velocity Global’s blend of strategic R&D investments and compliance expertise has transformed them into a critical partner for companies looking to accelerate global growth. Their comprehensive EOR solution allows organizations to focus on their expansion goals without the burden and potential risks of logistical and legal complexities." As a trailblazer in global workforce solutions, Velocity Global empowers companies to hire, manage, pay, and retain talent, anywhere in the world. Over the years, Velocity Global has evolved from offering a point solution to being a strategic partner to its customers as they execute on their global growth plans. Velocity Global’s powerful combination of its self-service Global Work Platform and its deep legal and HR expertise ensures seamless compliance, no matter how complex the jurisdiction. Both employers and employees benefit from a frictionless, user-friendly experience. In its 2024 report, NelsonHall highlights several strengths that contributed to Velocity Global’s positioning as a leader, including: Mature EOR market provider: Velocity Global offers a compliant, integrated EOR solution that enables multinational companies to confidently hire across borders. Technology roadmap: Velocity Global’s roadmap is centered on AI-driven enhancements, expanded platform integrations, and robust self-service functionality. Competitive service offerings beyond EOR: Velocity Global offers an array of services beyond EOR, including global benefits, immigration support, pensions, equity management, and office space logistics. ”The ability to hire anyone, anywhere is a huge differentiator as companies expand across geographies and tap into underutilized talent pools,” says Francoise Brougher, CEO of Velocity Global. “To simplify and streamline this process for customers, we invest in our technology. This, coupled with our extensive in-country and compliance expertise, means customers can have peace of mind and focus on growing their business.” This latest recognition reinforces Velocity Global’s unwavering commitment to empowering businesses with the tools and expertise to navigate the complexities of the global workforce landscape and drive sustained growth. To learn more about what sets us apart, download the report [ here ]. For more information on how Velocity Global makes opportunity borderless for people everywhere, visit www.velocityglobal.com. About Velocity Global Velocity Global gives you the power to build your team everywhere—combining seamless technology and local expertise in 185+ countries. We make it simple to compliantly hire, pay, manage, and retain talent anywhere. With Velocity Global, the world is yours. About NelsonHall NelsonHall is the leading global analyst firm dedicated to helping organizations understand the 'art of the possible' in digital operations transformation. With analysts in the U.S., U.K., Continental Europe, and Asia, NelsonHall provides buy-side organizations with detailed, critical information on markets and vendors (including NEAT assessments) that helps them make fast and highly informed sourcing decisions. And, for vendors, NelsonHall provides deep knowledge of market dynamics and user requirements to help them hone their go-to-market strategies. NelsonHall's analysis is based on rigorous, primary research, and is widely respected for the quality and depth of its insight. Media Contact: press@velocityglobal.com Contact Details Media contact +1 720-650-4348 press@velocityglobal.com Company Website https://velocityglobal.com/

October 01, 2024 07:47 AM Pacific Daylight Time

Image

How Cosmos Health’s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Benzinga

By James Blacker, Benzinga Global healthcare group Cosmos Health (NASDAQ: COSM) has potentially positioned itself for growth through its acquisition last year of Cana Laboratories, a Greek pharmaceutical company with nearly a century of expertise. As Cosmos’ new manufacturing arm, Cana brings a wealth of synergies, potentially enabling the company to control its own production, from pharmaceuticals to nutraceuticals. Cana Laboratories: A Century Of Expertise Founded in 1928, Cana Laboratories has earned its name in the pharmaceutical industry over nearly a century, having partnered with companies such as AstraZeneca (NASDAQ: AZN), Merck (NYSE: MRK), Janssen, Nestlé (OTC: NSRGY), Unilever (Unilever), Viatris (NASDAQ: VTRS) and Procter & Gamble (NYSE: PG). In recent years it has also worked with major firms in the medtech space, namely Medtronic (NYSE: MDT) and Stryker (NYSE: SYK). Cosmos acquired Cana in July of last year for around $1.67 million – a heavy discount compared to Cana’s $10 million valuation at the time, according to the company. As such, Cosmos expects to record a substantial gain on the purchase of what it now considers to be its crown jewel asset. The acquisition of Cana equips Cosmos with in-house manufacturing capabilities, bringing significant vertical integration and providing greater control over quality and costs. Cosmos can now use Cana’s facilities to manufacture its portfolio of generic medicines, including treatments for diabetes, cholesterol, respiratory and cardiac conditions, as well as its proprietary nutraceutical brand, Sky Premium Life. The acquisition has moreover added several brands to Cosmos’ portfolio, including antiseptics like C-Sept, the organic infant care line biobebe and dermocosmetics such as Eleon Cosmetics. New Facility To Scale Production Furthermore, Cosmos now owns Cana's 54,000 sq. ft. production facility in Athens. Certified by the European Medicines Agency and with a Good Manufacturing Practice license, this facility enhances Cosmos’ production capabilities, creating opportunities for potentially lucrative contract manufacturing agreements. Cosmos has invested some $5.5 million in Cana since the acquisition. The investment includes upgrading the Athens facility with new machinery, equipment, IT infrastructure and quality management systems. These investments will enable the company to manufacture a wide range of pharmaceuticals at scale, such as tablets, capsules, syrups, sprays, creams, gels and ointments. The company announced in July this year that it completed the first phase of this upgrade. At full capacity, which Cosmos says will be reached by the end of 2025, the facility is expected to generate over $10 million in annual gross profit. This stands in contrast to Cosmos’ current market cap of about $15 million as of Sept. 27. Contract Manufacturing: A High-Margin Growth Driver With its enhanced manufacturing capacity, Cosmos aims to accelerate the growth of its contract manufacturing business. In July, the company announced that it signed agreements with Provident Pharmaceuticals and Humacology to manufacture 5,020,000 units of medicines and up to 500,000 CBD units. Cosmos says its contract manufacturing business has very high margins thanks to minimal costs, most of which are borne by clients. The company, therefore, expects the newly signed deals to be highly profitable. Moreover, with less than 20% of its production capacity being utilized, there is plenty of room to sign additional contracts. Further down the line, if the facility reaches full capacity, Cosmos is prepared to initiate a second phase of the expansion to further boost capacity and gross profits beyond the projected $10 million from phase 1. Cosmos Health says it is confident that the acquisition of Cana Laboratories positions it for substantial growth. With its new in-house production capabilities, the company can boost efficiency and secure high-margin contract manufacturing agreements. Interested investors may want to watch for announcements of further contract manufacturing agreements as Cosmos seeks to fully utilize its production capacity. Featured photo by Testalize.me on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

October 01, 2024 09:30 AM Eastern Daylight Time

Image

Forum Health Launches Revolutionary PNOĒ Metabolic Device Transforming Weight Management, Fitness and Longevity

Forum Health

Forum Health, a premier provider of personalized integrative and functional medicine, announces the launch of the PNOĒ metabolic analysis device, offering precise insights into metabolic, heart, lung, and cellular health for personalized wellness. Now available in Forum Health’s Madison and Fond du Lac, Wisconsin clinics, the PNOĒ uses a data-driven approach to weight management, fitness, and longevity optimization. Schedule a PNOĒ assessment here: Fond du Lac or Madison. Julie Heyrman, MD: "We’re thrilled to bring this advanced technology to our patients in Wisconsin. The PNOĒ allows us to better tailor health solutions that address the root causes of weight gain, fatigue, aging, and cardiovascular risk." Through using only breath, the PNOĒ provides a comprehensive metabolic analysis on how effectively the body burns calories, the efficiency of the heart and lungs, and overall cellular performance. Patients receive personalized health plans tailored to their unique metabolic profile for improved wellness and disease prevention. Key Benefits of PNOĒ Metabolic Analysis: Precision Weight Management: Analyzes metabolism to optimize workouts, calorie intake, and macronutrient balance for sustainable weight management. Endurance Enhancement: Measures the efficiency of heart, lungs, and cells, identifying limiting factors and providing a customized plan to overcome them. Longevity Optimization: Calculates VO2 max, cellular health, and metabolic efficiency—key predictors of lifespan and well-being. Early Detection - Detects early risk factors for heart, lung, and metabolic conditions, empowering proactive health steps. Phil Hagerman, CEO: “Forum Health is committed to bringing the most advanced technologies to our patients, and the PNOĒ device represents a new frontier in personalized healthcare. By offering precise metabolic insights, we can create tailored health plans that drive better outcomes for the health issues most affecting our patient's overall well-being.” About PNOĒ PNOĒ is a state-of-the-art metabolic analysis device that provides comprehensive assessments of heart, lung, and cellular fitness through breath analysis. Learn more at pnoe.com. About Forum Health, LLC Forum Health, LLC is a nationwide provider of personalized healthcare steeped in the powerful principles of functional and integrative medicine. Our providers take a root-cause approach to care exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. For more, visit www.forumhealth.com. Contact Details Britt Wittelsberger +1 410-852-0738 bwittelsberger@forumhealth.com Company Website https://forumhealth.com

October 01, 2024 08:50 AM Eastern Daylight Time

MediVera Compounding Pharmacy™ Expands into 18 States Across Five Regions in 2024, Now Offers Dozens of Personalized Medicine Options

MediVera

MediVera Compounding Pharmacy™, a leader in personalized medicine since 1999, announced today that it has officially been licensed to serve residents in 18 new states across the West, Southwest, Southeast, Midwest, and Northeast regions in 2024. The licenses allow MediVera to fill compounding prescriptions—including semaglutide and tirzepatide—throughout these states. This expansion broadens the company’s geographical reach, reflecting its commitment to providing personalized compounding services to prescribers and patients nationwide. The new states include: West Region: Colorado, Idaho, Montana, Utah, Washington, Wyoming Southwest Region: Arizona, New Mexico, Oklahoma Southeast Region: Georgia, North Carolina, South Carolina, Tennessee, Virginia, West Virginia Midwest Region: South Dakota Northeast Region: Connecticut, Maine The licenses were issued between January 24, 2024, and August 13, 2024, by the respective State Boards of Pharmacy following rigorous application and compliance processes that require MediVera to meet or exceed governmental regulations and recommendations. MediVera is PCAB Accredited in both sterile and non-sterile compounding, certifying ethical and quality standards met by only 1% of compounding pharmacies nationwide. Prescribers and patients in these states are now welcome to use MediVera’s services, effective immediately. “We are absolutely thrilled with the opportunity to do business in these new states,” said MediVera CEO Bradley McCloskey, PharmD. “MediVera has been dedicated to changing lives with the industry standard in personalized medicine since it was founded by my father over 20 years ago. Bringing that simple mission to states across the country—and now to these additional 18 states—is a dream come true.” This growth coincides with an increased interest in compounded medications, including hormone replacement therapy and solutions for men’s and women’s health. MediVera has responded with an ongoing nationwide expansion effort, growing its footprint to include 37 states, with more licenses expected before the end of the year. About MediVera Since its inception in 1999, MediVera Compounding Pharmacy™ (formerly University Compounding Pharmacy) has been dedicated to providing personalized medicine. With a focus on quality and innovation, MediVera Compounding Pharmacy™ continues to set industry standards, offering tailored solutions to meet the unique needs of healthcare providers and patients. MediVera Compounding Pharmacy™ is currently licensed in and ships to the following 33 states: AZ, CN, CO, DE, FL, GA, IA, ID, IL, IN, KY, MA, MD, ME, MI, MN, MO, MT, NC, NH, NJ, NY, OH, PA, RI, SC, SD, TN, VA, VT, WA, WI, WY. Contact Details MediVera Compounding Pharmacy™ Laurie Malseed +1 937-242-0430 laurie@mediverarx.com Company Website https://mediverarx.com/

September 26, 2024 09:00 AM Eastern Daylight Time

Texicare Partners with TempoPay to Make Paying For Health Care Simpler and More Accessible for Small Business Groups in Texas

TempoPay

TempoPay, a flexible payment solution that helps bridge the affordability gap in health care, and Texicare, the health affiliate of Texas Mutual, today announced that employees of small business groups selecting Texicare health plans can now access TempoPay to help manage everyday healthcare expenses. TempoPay, a subsidiary of HPS/PayMedix, is a flexible payments platform that provides employees with the ability to pay their health care bills over time without interest, fees or credit checks. The TempoPay Visa® card can be used to pay for everything from medical care and prescriptions to vision and dental bills and other health and wellness-related costs not covered by employees’ plans. Texicare members can sign up to access $1,500 in interest-free financing through TempoPay any time and have the flexibility to choose repayment terms. By building this unique financial tool into the health plan, members can manage their out-of-pocket expenses in a way that works for them, keeping health care and well-being within the household budget. “For many Texans, out-of-pocket expenses are a barrier to getting needed care,” said Meredith Duncan, CEO of Texicare. “That’s why we’re partnering with TempoPay—to make health care more accessible for all our members so they can focus first and foremost on their well-being and manage their out-of-pocket costs in a way that works for them. Together, we are aligned in our mission to build a healthier, happier Texas.” Texicare aims to change the health care ecosystem by providing small businesses with innovative solutions that increase access to high-quality care. Texicare’s health plans are designed with the employee experience in mind—they are easy to use and focused on the holistic well-being of employees and their families. The addition of TempoPay will enhance these offerings and open access to small businesses across Texas, allowing employees to access health care when they need it. “TempoPay is a perfect fit for Texas employers who can now offer their employees a flexible way to pay for their health care expenses, and we are proud to be partnering with Texicare,” Erika Davison-Aviles, Co-founder of TempoPay said. “Through this partnership, we accelerate our mission to help hardworking people and their families get care when they need it and make health care accessible for all." About TempoPay TempoPay partners with employers to help their employees manage their medical costs with interest-free financing and flexible repayment options. With the TempoPay Visa ® card employees can take control of how they pay for healthcare without added stress, providing simple access to the financial security needed for happier, healthier lives. About Texicare Texicare, the health affiliate of Texas Mutual, is changing the health care ecosystem by providing small businesses with innovative solutions that increase access to easy-to-use, more affordable, quality health care for employees and Texas families. Texicare’s vision is to transform the health care ecosystem for the better, helping to create a healthier and happier Texas. To learn more about Texicare, visit www.texicare.com. Media Contacts: For Texicare, Emma Chase Red Fan Communications press@texicare.com 512-917-4319 For TempoPay Kaitlynn Cooney Brodeur Partners kcooney@brodeur.com 609-351-5944 Contact Details Brodeur Partners Kaitlynn Cooney +1 609-351-5944 kcooney@brodeur.com Company Website https://www.tempopay.com

September 25, 2024 08:00 AM Eastern Daylight Time

UNOS applauds House action to prohibit discrimination in organ transplants

United Network for Organ Sharing

Today, Maureen McBride, Ph.D., the CEO of the United Network for Organ Sharing (UNOS), issued the following statement after the U.S. House of Representatives passed the Charlotte Woodward Organ Transplant Discrimination Prevention Act. This legislation prohibits discrimination in organ transplantation against individuals with physical or intellectual disabilities. “The U.S. organ transplant matching system was created 40 years ago to serve every patient in need, which is why we strongly believe no one should be denied placement on the national waitlist solely because of his or her disability. We’re pleased to see the House pass this legislation, which advances our shared goal of ensuring equity for patients with disabilities in our nation’s donation and transplant system. Thank you, U.S. Reps. Kat Cammack and Debbie Dingell for your leadership. We look forward to continuing to work with you to ensure all Americans, regardless of their disability, have equitable access to organ transplants, and urge the U.S. Senate to quickly pass this legislation led by U.S. Sens. Marco Rubio and Maggie Hassan.” About UNOS United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant. Contact Details United Network for Organ Sharing Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

September 24, 2024 05:25 PM Eastern Daylight Time

Image

1 ... 5 6 7 8 9 ... 309